Tin Su
Concepts (410)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drosophila melanogaster | 31 | 2026 | 241 | 7.830 |
Why?
| | Drosophila Proteins | 26 | 2026 | 215 | 6.820 |
Why?
| | Drosophila | 19 | 2026 | 168 | 4.500 |
Why?
| | Radiation, Ionizing | 15 | 2026 | 86 | 4.240 |
Why?
| | Regeneration | 8 | 2026 | 198 | 2.910 |
Why?
| | Apoptosis | 19 | 2026 | 2454 | 2.730 |
Why?
| | Cell Cycle | 17 | 2020 | 600 | 2.000 |
Why?
| | Wings, Animal | 9 | 2026 | 38 | 1.670 |
Why?
| | Imaginal Discs | 6 | 2026 | 6 | 1.550 |
Why?
| | Mitosis | 12 | 2011 | 194 | 1.500 |
Why?
| | Caspases | 4 | 2020 | 233 | 1.420 |
Why?
| | DNA Damage | 15 | 2020 | 440 | 1.400 |
Why?
| | Neoplasms | 9 | 2026 | 2946 | 1.290 |
Why?
| | Animals | 68 | 2026 | 38410 | 1.240 |
Why?
| | Wnt1 Protein | 3 | 2022 | 8 | 1.190 |
Why?
| | Cell Cycle Proteins | 11 | 2017 | 633 | 1.110 |
Why?
| | Tumor Suppressor Protein p53 | 6 | 2020 | 536 | 1.080 |
Why?
| | Vaccines | 2 | 2023 | 389 | 1.060 |
Why?
| | Cell Plasticity | 2 | 2026 | 37 | 1.060 |
Why?
| | Protein Synthesis Inhibitors | 2 | 2025 | 48 | 1.030 |
Why?
| | STAT Transcription Factors | 2 | 2017 | 25 | 1.000 |
Why?
| | Morphogenesis | 3 | 2026 | 171 | 0.980 |
Why?
| | Matrix Metalloproteinase 1 | 1 | 2026 | 22 | 0.970 |
Why?
| | Larva | 9 | 2026 | 242 | 0.950 |
Why?
| | High-Throughput Screening Assays | 2 | 2023 | 178 | 0.950 |
Why?
| | Malaysia | 10 | 2026 | 15 | 0.910 |
Why?
| | Stem Cells | 3 | 2018 | 630 | 0.890 |
Why?
| | Protein Biosynthesis | 3 | 2025 | 452 | 0.880 |
Why?
| | Chromosomes | 3 | 2024 | 106 | 0.880 |
Why?
| | Peptides, Cyclic | 3 | 2020 | 273 | 0.840 |
Why?
| | Loss of Heterozygosity | 2 | 2024 | 52 | 0.840 |
Why?
| | Autophagy | 3 | 2026 | 291 | 0.840 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2026 | 222 | 0.830 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2231 | 0.820 |
Why?
| | Head and Neck Neoplasms | 3 | 2025 | 569 | 0.810 |
Why?
| | Cell Death | 5 | 2018 | 383 | 0.790 |
Why?
| | Radiation Tolerance | 3 | 2014 | 103 | 0.780 |
Why?
| | Radiation-Sensitizing Agents | 2 | 2015 | 43 | 0.780 |
Why?
| | Spindle Apparatus | 7 | 2011 | 95 | 0.770 |
Why?
| | Hematologic Neoplasms | 1 | 2025 | 169 | 0.760 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 79 | 0.760 |
Why?
| | Cell Phone | 2 | 2026 | 83 | 0.730 |
Why?
| | Models, Biological | 11 | 2020 | 1772 | 0.730 |
Why?
| | Drug Discovery | 2 | 2023 | 153 | 0.710 |
Why?
| | DNA Replication | 4 | 2010 | 250 | 0.670 |
Why?
| | Embryo, Nonmammalian | 6 | 2011 | 171 | 0.660 |
Why?
| | Intracellular Signaling Peptides and Proteins | 3 | 2021 | 459 | 0.650 |
Why?
| | Gene Expression Profiling | 2 | 2022 | 1794 | 0.640 |
Why?
| | Early Detection of Cancer | 3 | 2022 | 506 | 0.640 |
Why?
| | Wound Healing | 1 | 2023 | 361 | 0.630 |
Why?
| | DNA Repair | 6 | 2020 | 256 | 0.610 |
Why?
| | Transcription Factors | 4 | 2022 | 1747 | 0.610 |
Why?
| | Tumor Suppressor Proteins | 3 | 2021 | 323 | 0.600 |
Why?
| | Text Messaging | 1 | 2022 | 189 | 0.600 |
Why?
| | Glioblastoma | 1 | 2023 | 354 | 0.600 |
Why?
| | Peptide Hydrolases | 1 | 2020 | 105 | 0.600 |
Why?
| | Salivary Glands | 1 | 2019 | 36 | 0.580 |
Why?
| | Gastrula | 3 | 2004 | 17 | 0.570 |
Why?
| | Drugs, Investigational | 1 | 2019 | 31 | 0.570 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 196 | 0.550 |
Why?
| | Signal Transduction | 8 | 2026 | 5272 | 0.550 |
Why?
| | Epithelial Cells | 3 | 2026 | 1141 | 0.540 |
Why?
| | DNA-Binding Proteins | 8 | 2026 | 1488 | 0.520 |
Why?
| | Pyrophosphatases | 1 | 2017 | 27 | 0.520 |
Why?
| | Breast Neoplasms | 4 | 2024 | 2420 | 0.520 |
Why?
| | E2F1 Transcription Factor | 2 | 2024 | 68 | 0.510 |
Why?
| | Nuclear Proteins | 4 | 2009 | 745 | 0.510 |
Why?
| | Teaching | 2 | 2011 | 242 | 0.500 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2025 | 939 | 0.500 |
Why?
| | Gene Expression Regulation, Developmental | 7 | 2022 | 915 | 0.500 |
Why?
| | Microtubule-Associated Proteins | 2 | 2009 | 197 | 0.480 |
Why?
| | Telemedicine | 2 | 2023 | 978 | 0.470 |
Why?
| | Models, Animal | 1 | 2017 | 394 | 0.460 |
Why?
| | Humans | 50 | 2026 | 147293 | 0.460 |
Why?
| | Protein Kinases | 5 | 2021 | 312 | 0.440 |
Why?
| | Disease Models, Animal | 5 | 2020 | 4604 | 0.440 |
Why?
| | MicroRNAs | 2 | 2014 | 694 | 0.430 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2012 | 194 | 0.420 |
Why?
| | Quality of Life | 3 | 2026 | 3246 | 0.420 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2009 | 432 | 0.420 |
Why?
| | Phosphorylation | 8 | 2025 | 1721 | 0.420 |
Why?
| | Research | 1 | 2017 | 434 | 0.420 |
Why?
| | Methyl Methanesulfonate | 3 | 2010 | 7 | 0.410 |
Why?
| | Mutation | 13 | 2020 | 4130 | 0.400 |
Why?
| | Hypertension | 1 | 2022 | 1280 | 0.390 |
Why?
| | Heterozygote | 3 | 2024 | 317 | 0.380 |
Why?
| | Mutagens | 3 | 2010 | 27 | 0.380 |
Why?
| | Cell Lineage | 3 | 2026 | 381 | 0.360 |
Why?
| | RNA Interference | 4 | 2026 | 477 | 0.360 |
Why?
| | Genome, Insect | 1 | 2012 | 29 | 0.360 |
Why?
| | Neuropeptides | 2 | 2009 | 75 | 0.360 |
Why?
| | Climate Change | 2 | 2026 | 187 | 0.360 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 3565 | 0.350 |
Why?
| | Cell Survival | 5 | 2024 | 1111 | 0.340 |
Why?
| | Students | 2 | 2023 | 659 | 0.340 |
Why?
| | Chromosome Aberrations | 2 | 2024 | 168 | 0.340 |
Why?
| | Cross-Sectional Studies | 8 | 2026 | 6011 | 0.340 |
Why?
| | Cell Proliferation | 7 | 2025 | 2529 | 0.340 |
Why?
| | Cyclin A | 2 | 2001 | 17 | 0.340 |
Why?
| | Maytansine | 1 | 2011 | 18 | 0.340 |
Why?
| | Cancer Vaccines | 2 | 2025 | 164 | 0.330 |
Why?
| | Embryo, Mammalian | 2 | 2023 | 234 | 0.330 |
Why?
| | DNA, Satellite | 1 | 2010 | 18 | 0.330 |
Why?
| | Cell Division | 3 | 2005 | 758 | 0.320 |
Why?
| | E2F2 Transcription Factor | 1 | 2010 | 14 | 0.320 |
Why?
| | Hydrozoa | 1 | 2010 | 2 | 0.320 |
Why?
| | Paclitaxel | 1 | 2012 | 261 | 0.320 |
Why?
| | Metabolic Networks and Pathways | 1 | 2011 | 175 | 0.320 |
Why?
| | Membrane Proteins | 1 | 2017 | 1171 | 0.320 |
Why?
| | Educational Measurement | 2 | 2011 | 332 | 0.310 |
Why?
| | Adjuvants, Immunologic | 2 | 2023 | 245 | 0.310 |
Why?
| | Heterochromatin | 1 | 2010 | 68 | 0.310 |
Why?
| | Peer Group | 2 | 2011 | 258 | 0.310 |
Why?
| | Piperazines | 2 | 2024 | 375 | 0.300 |
Why?
| | Biology | 1 | 2011 | 89 | 0.300 |
Why?
| | Cell Differentiation | 3 | 2026 | 2054 | 0.300 |
Why?
| | Tyrosine | 1 | 2009 | 218 | 0.280 |
Why?
| | Genetics | 1 | 2009 | 23 | 0.280 |
Why?
| | Leprosy | 2 | 2019 | 25 | 0.280 |
Why?
| | CDC2 Protein Kinase | 3 | 2005 | 27 | 0.270 |
Why?
| | Learning | 2 | 2011 | 446 | 0.270 |
Why?
| | Cyclin E | 2 | 2007 | 23 | 0.270 |
Why?
| | Combined Modality Therapy | 5 | 2020 | 1281 | 0.270 |
Why?
| | Metaphase | 3 | 2005 | 34 | 0.260 |
Why?
| | Anaphase | 3 | 2005 | 19 | 0.260 |
Why?
| | Immunotherapy | 2 | 2025 | 672 | 0.260 |
Why?
| | Cell Movement | 2 | 2019 | 966 | 0.250 |
Why?
| | Chemokine CXCL5 | 1 | 2026 | 20 | 0.250 |
Why?
| | Extracellular Traps | 1 | 2026 | 53 | 0.240 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2026 | 56 | 0.230 |
Why?
| | Reactive Oxygen Species | 2 | 2026 | 616 | 0.230 |
Why?
| | Genes, cdc | 3 | 2006 | 11 | 0.230 |
Why?
| | Mice | 9 | 2025 | 18491 | 0.230 |
Why?
| | Gene Expression Regulation | 3 | 2009 | 2625 | 0.220 |
Why?
| | Ecological Momentary Assessment | 1 | 2026 | 49 | 0.220 |
Why?
| | Chromosomal Instability | 1 | 2004 | 21 | 0.210 |
Why?
| | Cisplatin | 2 | 2024 | 347 | 0.210 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2026 | 199 | 0.210 |
Why?
| | MAP Kinase Signaling System | 3 | 2024 | 308 | 0.210 |
Why?
| | Telomere | 2 | 2006 | 298 | 0.210 |
Why?
| | Tubulin | 1 | 2005 | 146 | 0.210 |
Why?
| | CDC2-CDC28 Kinases | 1 | 2004 | 16 | 0.210 |
Why?
| | Peroxiredoxins | 1 | 2024 | 25 | 0.200 |
Why?
| | Photoreceptor Cells, Invertebrate | 1 | 2003 | 4 | 0.200 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2024 | 46 | 0.200 |
Why?
| | Alleles | 3 | 2020 | 909 | 0.200 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2025 | 169 | 0.200 |
Why?
| | Arthropods | 1 | 2004 | 12 | 0.200 |
Why?
| | Mental Disorders | 2 | 2026 | 1188 | 0.200 |
Why?
| | Adjuvants, Pharmaceutic | 1 | 2023 | 15 | 0.200 |
Why?
| | Radioimmunotherapy | 1 | 2023 | 25 | 0.200 |
Why?
| | Curriculum | 1 | 2011 | 1082 | 0.200 |
Why?
| | Pyrimidinones | 1 | 2024 | 125 | 0.200 |
Why?
| | Vertebrates | 1 | 2004 | 63 | 0.200 |
Why?
| | RNA-Binding Proteins | 2 | 2026 | 451 | 0.200 |
Why?
| | Flow Cytometry | 3 | 2022 | 1172 | 0.190 |
Why?
| | Organogenesis | 1 | 2003 | 63 | 0.190 |
Why?
| | Embryonic Stem Cells | 1 | 2023 | 124 | 0.190 |
Why?
| | Telomere-Binding Proteins | 1 | 2004 | 120 | 0.190 |
Why?
| | Albumins | 1 | 2023 | 119 | 0.190 |
Why?
| | Exercise | 2 | 2026 | 2219 | 0.190 |
Why?
| | Cytoskeleton | 1 | 2004 | 193 | 0.190 |
Why?
| | Indonesia | 1 | 2022 | 23 | 0.190 |
Why?
| | Vietnam | 1 | 2022 | 27 | 0.190 |
Why?
| | Gene Expression | 2 | 2018 | 1481 | 0.180 |
Why?
| | Antigens, Neoplasm | 2 | 2025 | 273 | 0.180 |
Why?
| | Bangladesh | 1 | 2022 | 64 | 0.180 |
Why?
| | Immunoprecipitation | 3 | 2009 | 149 | 0.180 |
Why?
| | Pyridones | 1 | 2024 | 210 | 0.180 |
Why?
| | Review Literature as Topic | 1 | 2022 | 53 | 0.180 |
Why?
| | Cell Line | 4 | 2023 | 2832 | 0.180 |
Why?
| | Cell Separation | 2 | 2022 | 306 | 0.180 |
Why?
| | India | 1 | 2022 | 221 | 0.180 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2001 | 72 | 0.170 |
Why?
| | Microscopy, Confocal | 4 | 2007 | 322 | 0.170 |
Why?
| | Neurofibromin 2 | 2 | 2021 | 3 | 0.170 |
Why?
| | Checkpoint Kinase 2 | 4 | 2010 | 27 | 0.170 |
Why?
| | Telephone | 1 | 2022 | 177 | 0.170 |
Why?
| | Escherichia coli Infections | 1 | 2022 | 125 | 0.170 |
Why?
| | Epigenesis, Genetic | 1 | 2026 | 708 | 0.160 |
Why?
| | Prevalence | 3 | 2023 | 2889 | 0.160 |
Why?
| | Blotting, Western | 4 | 2009 | 1186 | 0.160 |
Why?
| | Food Services | 1 | 2020 | 21 | 0.160 |
Why?
| | Lymph Nodes | 1 | 2023 | 514 | 0.160 |
Why?
| | Cetuximab | 1 | 2020 | 111 | 0.160 |
Why?
| | Female | 18 | 2026 | 80076 | 0.160 |
Why?
| | Intracellular Space | 1 | 2020 | 64 | 0.160 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 55 | 0.160 |
Why?
| | Phthalazines | 1 | 2020 | 63 | 0.150 |
Why?
| | Poverty | 1 | 2024 | 533 | 0.150 |
Why?
| | Immunogenicity, Vaccine | 1 | 2020 | 40 | 0.150 |
Why?
| | Pyridines | 1 | 2024 | 610 | 0.150 |
Why?
| | Feeding Behavior | 1 | 2026 | 693 | 0.150 |
Why?
| | Biological Evolution | 1 | 2004 | 473 | 0.150 |
Why?
| | Neoplastic Stem Cells | 2 | 2023 | 409 | 0.150 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2020 | 187 | 0.150 |
Why?
| | Diacylglycerol Kinase | 1 | 2019 | 5 | 0.150 |
Why?
| | Perception | 1 | 2022 | 378 | 0.150 |
Why?
| | DNA | 2 | 2005 | 1444 | 0.150 |
Why?
| | rac GTP-Binding Proteins | 1 | 2019 | 35 | 0.150 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2023 | 379 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 429 | 0.140 |
Why?
| | Mental Health | 1 | 2026 | 813 | 0.140 |
Why?
| | Radiobiology | 1 | 2019 | 7 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 1166 | 0.140 |
Why?
| | Embryonic Development | 1 | 2000 | 125 | 0.140 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 137 | 0.140 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2000 | 167 | 0.140 |
Why?
| | Molecular Imaging | 1 | 2019 | 58 | 0.140 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2018 | 153 | 0.140 |
Why?
| | Checkpoint Kinase 1 | 4 | 2006 | 27 | 0.140 |
Why?
| | Pandemics | 2 | 2024 | 1720 | 0.140 |
Why?
| | Phenotype | 3 | 2018 | 3216 | 0.130 |
Why?
| | Transients and Migrants | 1 | 2017 | 28 | 0.130 |
Why?
| | S Phase | 2 | 2010 | 78 | 0.130 |
Why?
| | Escherichia coli | 1 | 2022 | 836 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 445 | 0.130 |
Why?
| | Gene Silencing | 2 | 2016 | 203 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 6164 | 0.130 |
Why?
| | Protein Transport | 1 | 2018 | 442 | 0.130 |
Why?
| | Rural Population | 1 | 2022 | 684 | 0.120 |
Why?
| | Research Design | 1 | 2023 | 1157 | 0.120 |
Why?
| | Radiation Injuries, Experimental | 1 | 2016 | 20 | 0.120 |
Why?
| | Cell Culture Techniques | 1 | 2019 | 375 | 0.120 |
Why?
| | Liver Neoplasms | 1 | 2023 | 787 | 0.120 |
Why?
| | Cell Polarity | 1 | 2017 | 137 | 0.120 |
Why?
| | Biomarkers | 3 | 2026 | 4351 | 0.120 |
Why?
| | Cells, Cultured | 2 | 2019 | 4169 | 0.110 |
Why?
| | Receptors, TIE | 1 | 2015 | 1 | 0.110 |
Why?
| | Aging | 1 | 2026 | 1992 | 0.110 |
Why?
| | Cost of Illness | 1 | 2017 | 327 | 0.110 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3448 | 0.110 |
Why?
| | Genetic Testing | 1 | 2017 | 493 | 0.110 |
Why?
| | Fluorescent Antibody Technique | 2 | 2005 | 365 | 0.100 |
Why?
| | Adult | 6 | 2024 | 41405 | 0.100 |
Why?
| | Qualitative Research | 1 | 2022 | 1735 | 0.100 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2015 | 269 | 0.100 |
Why?
| | HeLa Cells | 1 | 2015 | 633 | 0.100 |
Why?
| | Male | 11 | 2026 | 73950 | 0.100 |
Why?
| | Time Factors | 5 | 2005 | 7173 | 0.100 |
Why?
| | Middle Aged | 4 | 2024 | 36821 | 0.090 |
Why?
| | Cyclin-Dependent Kinases | 2 | 2004 | 122 | 0.090 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2020 | 141 | 0.090 |
Why?
| | X-Rays | 2 | 2004 | 27 | 0.090 |
Why?
| | Drug Synergism | 2 | 2024 | 355 | 0.090 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2011 | 23 | 0.090 |
Why?
| | Colorectal Neoplasms | 1 | 2020 | 876 | 0.090 |
Why?
| | Embryology | 1 | 2011 | 1 | 0.080 |
Why?
| | HCT116 Cells | 1 | 2011 | 76 | 0.080 |
Why?
| | Brain | 1 | 2004 | 3009 | 0.080 |
Why?
| | Tuberous Sclerosis | 1 | 2011 | 56 | 0.080 |
Why?
| | Glioma | 1 | 2015 | 432 | 0.080 |
Why?
| | Mice, Nude | 2 | 2024 | 680 | 0.080 |
Why?
| | Mitotic Index | 1 | 2010 | 25 | 0.080 |
Why?
| | Cyclins | 2 | 2001 | 79 | 0.080 |
Why?
| | Drug Design | 1 | 2011 | 177 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 751 | 0.080 |
Why?
| | Young Adult | 3 | 2022 | 14437 | 0.080 |
Why?
| | Aged | 4 | 2026 | 26514 | 0.080 |
Why?
| | Green Fluorescent Proteins | 2 | 2008 | 407 | 0.080 |
Why?
| | Aged, 80 and over | 1 | 2022 | 8430 | 0.080 |
Why?
| | Amino Acid Sequence | 2 | 2003 | 2134 | 0.070 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 143 | 0.070 |
Why?
| | Cell Nucleus | 2 | 2003 | 589 | 0.070 |
Why?
| | Goals | 1 | 2011 | 186 | 0.070 |
Why?
| | Molecular Sequence Data | 2 | 2003 | 2886 | 0.070 |
Why?
| | Feasibility Studies | 2 | 2026 | 1147 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2009 | 377 | 0.070 |
Why?
| | Biological Products | 1 | 2012 | 258 | 0.070 |
Why?
| | Gene Deletion | 2 | 2015 | 392 | 0.070 |
Why?
| | Kinetochores | 1 | 2008 | 52 | 0.070 |
Why?
| | China | 2 | 2019 | 278 | 0.070 |
Why?
| | Survival Analysis | 1 | 2011 | 1386 | 0.070 |
Why?
| | Gene Dosage | 1 | 2008 | 145 | 0.070 |
Why?
| | Xenopus | 2 | 2005 | 87 | 0.060 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 2218 | 0.060 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 149 | 0.060 |
Why?
| | E2F Transcription Factors | 1 | 2007 | 65 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2026 | 1776 | 0.060 |
Why?
| | Comprehension | 1 | 2009 | 188 | 0.060 |
Why?
| | Cytokinesis | 1 | 2007 | 50 | 0.060 |
Why?
| | Mycoplasma pneumoniae | 1 | 2026 | 54 | 0.060 |
Why?
| | Adolescent | 5 | 2026 | 22825 | 0.060 |
Why?
| | Nanoparticles | 2 | 2025 | 524 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1338 | 0.060 |
Why?
| | Healthy Aging | 1 | 2026 | 44 | 0.060 |
Why?
| | Microscopy, Fluorescence | 2 | 2005 | 409 | 0.060 |
Why?
| | Gastrin-Releasing Peptide | 1 | 2005 | 6 | 0.060 |
Why?
| | Chromatography, Affinity | 1 | 2005 | 82 | 0.060 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 110 | 0.060 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2006 | 55 | 0.060 |
Why?
| | Centrosome | 1 | 2005 | 72 | 0.060 |
Why?
| | Acid Anhydride Hydrolases | 1 | 2004 | 8 | 0.050 |
Why?
| | Transgenes | 1 | 2005 | 190 | 0.050 |
Why?
| | Enzyme Activation | 1 | 2006 | 762 | 0.050 |
Why?
| | Models, Genetic | 2 | 2006 | 536 | 0.050 |
Why?
| | ROC Curve | 1 | 2026 | 626 | 0.050 |
Why?
| | DNA Repair Enzymes | 1 | 2004 | 30 | 0.050 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2004 | 69 | 0.050 |
Why?
| | Melanoma, Experimental | 1 | 2025 | 109 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 780 | 0.050 |
Why?
| | Cleavage Stage, Ovum | 1 | 2004 | 6 | 0.050 |
Why?
| | Embryonic and Fetal Development | 1 | 2004 | 93 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2012 | 2812 | 0.050 |
Why?
| | MCF-7 Cells | 1 | 2024 | 133 | 0.050 |
Why?
| | Retinoblastoma Protein | 1 | 2004 | 62 | 0.050 |
Why?
| | Egg Proteins | 1 | 2004 | 20 | 0.050 |
Why?
| | Invertebrates | 1 | 2004 | 21 | 0.050 |
Why?
| | Gene Targeting | 1 | 2004 | 81 | 0.050 |
Why?
| | Bromodeoxyuridine | 1 | 2004 | 77 | 0.050 |
Why?
| | Endoderm | 1 | 2023 | 21 | 0.050 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2004 | 36 | 0.050 |
Why?
| | Macaca fascicularis | 1 | 2023 | 70 | 0.050 |
Why?
| | Fertilization | 1 | 2004 | 44 | 0.050 |
Why?
| | Macromolecular Substances | 1 | 2004 | 216 | 0.050 |
Why?
| | Glycosyltransferases | 1 | 2023 | 16 | 0.050 |
Why?
| | X Chromosome | 1 | 2003 | 66 | 0.050 |
Why?
| | Crosses, Genetic | 1 | 2003 | 123 | 0.050 |
Why?
| | Models, Anatomic | 1 | 2004 | 87 | 0.050 |
Why?
| | Substrate Specificity | 1 | 2004 | 387 | 0.050 |
Why?
| | Coculture Techniques | 1 | 2023 | 247 | 0.050 |
Why?
| | Body Patterning | 1 | 2004 | 138 | 0.050 |
Why?
| | Africa | 1 | 2023 | 119 | 0.050 |
Why?
| | Accelerometry | 1 | 2024 | 126 | 0.050 |
Why?
| | Protective Factors | 1 | 2023 | 102 | 0.050 |
Why?
| | Sequence Alignment | 1 | 2003 | 362 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 980 | 0.050 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 387 | 0.050 |
Why?
| | DNA Transposable Elements | 1 | 2003 | 125 | 0.050 |
Why?
| | Tretinoin | 1 | 2023 | 125 | 0.050 |
Why?
| | Mammals | 1 | 2004 | 286 | 0.050 |
Why?
| | Mass Spectrometry | 1 | 2005 | 728 | 0.040 |
Why?
| | Recombination, Genetic | 1 | 2003 | 205 | 0.040 |
Why?
| | Telomerase | 1 | 2004 | 250 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2003 | 567 | 0.040 |
Why?
| | 14-3-3 Proteins | 1 | 2001 | 15 | 0.040 |
Why?
| | Fertility | 1 | 2003 | 175 | 0.040 |
Why?
| | beta-Lactamases | 1 | 2022 | 54 | 0.040 |
Why?
| | Insect Proteins | 1 | 2001 | 40 | 0.040 |
Why?
| | Child | 3 | 2026 | 22979 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2004 | 480 | 0.040 |
Why?
| | Health Surveys | 1 | 2023 | 522 | 0.040 |
Why?
| | Plasmids | 1 | 2022 | 373 | 0.040 |
Why?
| | Amino Acid Motifs | 1 | 2001 | 219 | 0.040 |
Why?
| | Cytoplasm | 1 | 2001 | 255 | 0.040 |
Why?
| | Saccharomyces cerevisiae | 1 | 2005 | 584 | 0.040 |
Why?
| | Temperature | 1 | 2004 | 638 | 0.040 |
Why?
| | Neutrophils | 1 | 2026 | 1135 | 0.040 |
Why?
| | DNA End-Joining Repair | 1 | 2020 | 22 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2020 | 90 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2022 | 367 | 0.040 |
Why?
| | Ubiquitination | 1 | 2021 | 119 | 0.040 |
Why?
| | Virulence Factors | 1 | 2022 | 175 | 0.040 |
Why?
| | Health Education | 1 | 2023 | 346 | 0.040 |
Why?
| | Mass Media | 1 | 2020 | 39 | 0.040 |
Why?
| | Blastoderm | 1 | 2000 | 1 | 0.040 |
Why?
| | Theranostic Nanomedicine | 1 | 2020 | 15 | 0.040 |
Why?
| | Clone Cells | 1 | 2020 | 263 | 0.040 |
Why?
| | DNA, Neoplasm | 1 | 2020 | 163 | 0.040 |
Why?
| | Proteolysis | 1 | 2021 | 173 | 0.040 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.040 |
Why?
| | Biological Factors | 1 | 2020 | 39 | 0.040 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2000 | 67 | 0.040 |
Why?
| | Cell Size | 1 | 2000 | 94 | 0.040 |
Why?
| | Base Sequence | 1 | 2003 | 2175 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1730 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2023 | 449 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2000 | 153 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 289 | 0.040 |
Why?
| | Heat-Shock Response | 1 | 2000 | 78 | 0.040 |
Why?
| | Cell Count | 1 | 2000 | 321 | 0.040 |
Why?
| | Phylogeny | 1 | 2003 | 924 | 0.040 |
Why?
| | Nanotechnology | 1 | 2020 | 114 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2020 | 209 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2003 | 2030 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 889 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2025 | 932 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2020 | 502 | 0.030 |
Why?
| | Histones | 1 | 2004 | 672 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 239 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 268 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 984 | 0.030 |
Why?
| | Cognition | 1 | 2026 | 1286 | 0.030 |
Why?
| | Prognosis | 1 | 2026 | 4383 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 200 | 0.030 |
Why?
| | Microscopy | 1 | 2019 | 148 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 638 | 0.030 |
Why?
| | Schools | 1 | 2020 | 453 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2004 | 3153 | 0.030 |
Why?
| | Dendritic Cells | 1 | 2020 | 510 | 0.030 |
Why?
| | Kidney | 1 | 2024 | 1511 | 0.030 |
Why?
| | Receptor, TIE-2 | 1 | 2015 | 11 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2000 | 566 | 0.030 |
Why?
| | Algorithms | 1 | 2023 | 1868 | 0.030 |
Why?
| | Protein Binding | 1 | 2021 | 2249 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1457 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1456 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 2001 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 6041 | 0.020 |
Why?
| | Health Promotion | 1 | 2020 | 792 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2020 | 2017 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2020 | 1431 | 0.020 |
Why?
| | Child, Preschool | 1 | 2026 | 12016 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 1940 | 0.020 |
Why?
| | Risk Factors | 1 | 2020 | 11017 | 0.010 |
Why?
| | Xenopus Proteins | 1 | 2005 | 36 | 0.010 |
Why?
| | G2 Phase | 1 | 2005 | 39 | 0.010 |
Why?
| | Hydroxyurea | 1 | 2005 | 35 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2005 | 273 | 0.010 |
Why?
| | RNA | 1 | 2005 | 916 | 0.010 |
Why?
|
|
Su's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|